ANGIODYNAMICS INC Segments Disclosure
| Year ended May 31, | |||||||||||||||||
| (in thousands) | 2025 | 2024 | 2023 | ||||||||||||||
| Med Tech Net Sales | $ | 126,653 | $ | 106,403 | $ | 96,687 | |||||||||||
| Med Tech Cost of Sales (exclusive of intangible amortization) | $ | 48,138 | $ | 39,205 | $ | 34,721 | |||||||||||
| Gross Margin | $ | 78,515 | $ | 67,198 | $ | 61,966 | |||||||||||
| Gross Margin % | 62.0 | % | 63.2 | % | 64.1 | % | |||||||||||
| Med Device Net Sales | $ | 165,845 | $ | 197,511 | $ | 242,065 | |||||||||||
| Med Device Cost of Sales (exclusive of intangible amortization) | $ | 86,655 | $ | 110,011 | $ | 129,785 | |||||||||||
| Gross Margin | $ | 79,190 | $ | 87,500 | $ | 112,280 | |||||||||||
| Gross Margin % | 47.7 | % | 44.3 | % | 46.4 | % | |||||||||||
| Total Net Sales | $ | 292,498 | $ | 303,914 | $ | 338,752 | |||||||||||
| Total Cost of Sales (exclusive of intangible amortization) | $ | 134,793 | $ | 149,216 | $ | 164,506 | |||||||||||
| Gross Margin | $ | 157,705 | $ | 154,698 | $ | 174,246 | |||||||||||
| Gross Margin % | 53.9 | % | 50.9 | % | 51.4 | % | |||||||||||
Operating expenses(1) | $ | 197,659 | $ | 401,632 | $ | 225,427 | |||||||||||
Gain on sale of assets(2) | — | 54,499 | — | ||||||||||||||
Other income (expense), net(3) | 5,922 | 797 | (3,256) | ||||||||||||||
| Loss before income tax benefit | $ | (34,032) | $ | (191,638) | $ | (54,437) | |||||||||||
| Year ended May 31, | |||||||||||||||||
| (in thousands) | 2025 | 2024 | 2023 | ||||||||||||||
| Net sales by Geography | |||||||||||||||||
| United States | $ | 250,983 | $ | 251,486 | $ | 282,713 | |||||||||||
| International | 41,515 | 52,428 | 56,039 | ||||||||||||||
| Total | $ | 292,498 | $ | 303,914 | $ | 338,752 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Jul 18, 2025 | Showing above |
| 2024 | Jul 25, 2024 | |
| 2023 | Aug 3, 2023 | |
| 2022 | Jul 22, 2022 | |
| 2021 | Jul 27, 2021 | |
| 2020 | Aug 10, 2020 | |
| 2019 | Jul 25, 2019 | |
| 2018 | Jul 23, 2018 | |
| 2017 | Aug 4, 2017 | |
| 2016 | Aug 1, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.